Molecular docking analysis of the protein–protein interaction between RelA‐associated inhibitor and tumor suppressor protein p53 and its inhibitory effect on p53 action

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer Science

• Publication date

  2008-03-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1111/j.1349-7006.2007.00723.xPMID 18201273PMCID PMC11158167
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• NF-κB Signaling and Carcinogenesis

  2007cited by this paper
• Identification of a novel isoform of iASPP and its interaction with p53.

  2007cited by this paper
• NF-kappa B signaling and carcinogenesis.

  2007cited by this paper
• p53 alterations in human cancer: more questions than answers

  2007cited by this paper
• p53 mutation heterogeneity in cancer.

  2005cited by this paper
• A mutation in NFkB interacting protein 1 results in cardiomyopathy and abnormal skin development in wa3 mice.

  2005cited by this paper
• The expression of iASPP in acute leukemias.

  2005cited by this paper
• The N-terminus of a novel isoform of human iASPP is required for its cytoplasmic localization

  2004cited by this paper
• Expression of 53BP2 and ASPP2 proteins from TP53BP2 gene by alternative splicing.

  2004cited by this paper
• iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human

  2003cited by this paper
• RING Finger Protein AO7 Supports NF-κB-mediated Transcription by Interacting with the Transactivation Domain of the p65 Subunit*

  2003cited by this paper
• RelA-Associated Inhibitor Blocks Transcription of Human Immunodeficiency Virus Type 1 by Inhibiting NF-κB and Sp1 Actions

  2002cited by this paper
• Involvement of the Pro-oncoprotein TLS (Translocated in Liposarcoma) in Nuclear Factor-κB p65-mediated Transcription as a Coactivator*

  2001cited by this paper
• ASPP proteins specifically stimulate the apoptotic function of p53.

  2001cited by this paper
• Residue frequencies and pairing preferences at protein–protein interfaces

  2001cited by this paper
• Inhibition of Nuclear Factor-κB-mediated Transcription by Association with the Amino-terminal Enhancer of Split, a Groucho-related Protein Lacking WD40 Repeats*

  2000cited by this paper
• BiGGER: A new (soft) docking algorithm for predicting protein interactions

  2000cited by this paper
• NF-κB subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2

  1999cited by this paper
• Identification of a Novel Inhibitor of Nuclear Factor-κB, RelA-associated Inhibitor*

  1999cited by this paper
• Sensitization of cancer cells to DNA damage-induced cell death by specific cell cycle G2 checkpoint abrogation.

  1999cited by this paper
• NF-kappaB subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2.

  1999cited by this paper
• Inhibition of human immunodeficiency virus type 1 replication by a bioavailable serine/threonine kinase inhibitor, fasudil hydrochloride.

  1998cited by this paper
• Butyrate Activates the WAF1/Cip1 Gene Promoter through Sp1 Sites in a p53-negative Human Colon Cancer Cell Line*

  1997cited by this paper
• The p53-binding protein 53BP2 also interacts with Bc12 and impedes cell cycle progression at G2/M

  1996cited by this paper
• Structure of the p53 Tumor Suppressor Bound to the Ankyrin and SH3 Domains of 53BP2

  1996cited by this paper
• Tumor suppressor p53 is a direct transcriptional activator of the human bax gene.

  1995cited by this paper
• A novel form of Epstein-Barr virus latency in normal B cells in vivo.

  1995cited by this paper
• The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.

  1993cited by this paper
• Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.

  1993cited by this paper
• Suppression of human colorectal carcinoma cell growth by wild-type p53.

  1990cited by this paper

• Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf

  2019cites this paper
• Sequence variation in PPP1R13L results in a novel form of cardio‐cutaneous syndrome

  2017cites this paper
• Predicting malignancy in pre-neoplastic lesions detected during screening for pancreatic cancer

  2017cites this paper
• Insilico docking evaluation of bacterial derived anticancer (Lectin) Protein with different oncogene protein

  2015cites this paper
• Highly homologous proteins exert opposite biological activities by using different interaction interfaces

  2015cites this paper
• Identification by high-throughput in silico screening of radio-protecting compounds targeting the DNA-binding domain of the tumor suppressor p53.

  2013cites this paper
• Modeling the relationship between the p53 C-terminal domain and its binding partners using molecular dynamics.

  2010cites this paper